Collectively, our findings provide strong evidence that MARCO inhibition significantly enhances the anti-tumor immune response of anti-PD-1 immunotherapy by suppressing MARCO expression and MDSC differentiation, altering TAM properties, and promoting the infiltration of CD8+ T cells and NK cells. The gene discussed is PDCD1; the disease is neoplasm.